IMIgnace Mpio

Ignace Mpio

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ignace Mpio has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Le caractère non pro-inflammatoire de l’HDF est un atout dans la prise en charge des complications nutritionnelles, anémiques et ostéodystrophiques

    by I. Mpio

    Introduction: Il y a consensus sur le fait que l’hémodiafiltration en ligne (HDF) combinant l’épuration par diffusion et par convection est non pro-inflammatoire. Dès lors, il est intéressant d’analyser l’évolution de différents paramètres en rapport avec l’inflammation après un transfert des patients (pts) de l’hémodialyse conventionnelle (HDC) vers l’HDF. Patients et méthodes Travail prospectif chez 35 patients transférés d’HDC vers l’HDF au démarrage de la méthode convective dans l’établissement, n’ayant eu aucun replis en HDC pendant la période analysée de 12 mois. Il s’agit de 16 femmes (46 %) et de 19 hommes (54 %), âge moyen 72 ± 12 ans, ancienneté de dialyse 7 ± 6 ans. Caractéristiques techniques d’HDF : débit sanguin 300–400 mL/min, débit du dialysat ≥ 600 mL/min, volume de substitution 20 à 24 L, membrane de haute perméabilité (superficie ≥ 1,9 m2 et coefficient d’ultrafiltration ≥ 40 mL/h/mmHg), mode post-dilution. Paramètres protocolaires prédialytiques mesurés en phase HDC, à 6 et 9 mois sous HDF : dose de dialyse (KT), taux de B2-m, CRP, phosphatémie (P), parathormone intacte (PTHi), albuminémie (Alb), hémoglobine (Hb). Résultats: Les résultats sont résumés dans le Tableau 1. Discussion: À moyen et long terme (6 et 12 mois) on observe une baisse des indicateurs de l’inflammatoire (B2-m, CRP, PTHi), le maintien de l’équilibre nutritionnel, le contrôle de l’anémie et l’amélioration du syndrome ostéodystrophique facilitée probablement par la normalisation de P et PTHi comme le montrent les résultats de notre travail. Conclusion: Les épurations convectives en HDF lui confèrent l’avantage du contrôle de l’inflammation impactant favorablement par ce biais sur la prise en charge des complications urémiques.

  • Avantages de la convection en dialyse chronique. Résultats d’un travail prospectif d’un an

    by I. Mpio

    Introduction: L’hémodiafiltration en ligne (HDF) a été introduite dans l’arsenal thérapeutique de suppléance rénale dans les années 1980. Les études multicentriques (DOPPS, CONTRAST, Turkish HDF, ESHOL) ont rapporté une réduction de la morbi-mortalité par rapport à l’hémodialyse conventionnelle (HCV). Notre travail rapporte ses autres atouts majeurs. Patients et méthodes Notre étude comparative (HCV versus HDF) est prospective sur 1 an et concerne 35 patients (pts) transférés d’HCV en HDF au démarrage de ce mode de dialyse dans notre établissement. Caractères généraux des pts : 19 hommes (54 %), âge moyen 72 ± 12 ans, ancienneté de dialyse 7 ± 6 ans. Caractéristiques techniques de l’HDF : mode post-dilution, débit sanguin 300–400 mL/min, débit du dialysat ≥ 600 mL/min, volume de substitution 5 à 6 L/h, membrane de haute perméabilité. Paramètres clinicobiologiques avant dialyse à j0 phase HCV, puis après 1 an d’HDF : β2m, CRP, parathormone intacte (PTHi), phosphates, pression artérielle (PA) en fonction du traitement antihypertenseur (ahta), pression pulsée (PP), doses d’érythropoïétine (EPO), hémoglobine (Hb), les analyses biologiques ont été réalisées par un laboratoire assermenté. Résultats: Tableau 1 : (valeurs médianes, statistiques par Statview). Discussion: Les taux de β2m, CRP et de PTHi baissent significativement en HDF ; à bilan martial et taux d’Hb équivalents les doses d’EPO y sont plus basses. L’HDF facilite le contrôle de l’hypertension, sans effet sur la compliance artérielle. Conclusion: Les avantages en transferts convectifs de l’HDF engendrent une réduction du tryptique inflammation, anémie, ostéodystrophie et renforcent les ahta.

  • Résultats des stratégies thérapeutiques au cours de la dénutrition en hémodialyse chronique : étude prospective sur 12 mois

    by Ignace Mpio, Christine Cleaud, Walid Arkouche, Maurice Laville

    Undernutrition (UN) in chronic hemodialysis (CHD) is a recurrent complication and constitutes a major public health problem. This work aims to evaluate the effects of our nutritional strategy (NS) developed among malnourished patients (pts) in CHD. This is a prospective observational study conducted for 12 months (M) in a cohort of 132 pts in CHD including 49 women, mean age 66 ± 16 years and the dialysis vintage 72 ± 74 months. This NS is based on the action of a multidisciplinary team; it provides for moderate UN pts one first phase of an optimization of protein and energy intake in the daily meals; then depending on the clinical course a second phase of oral supplementation at home. For severe UN pts, the optimization of daily meals and the oral supplements at home are reinforced with perdialytic oral supplementation. This modality was also prescribed for moderate UN pts with poor compliance at home. In case of loss of appetite, anorexia, gastrointestinal intolerance or inadequate oral intakes the relay is made by the intradialytic parenteral nutrition (IPN). Methods consist in the evaluation of the serum albumin (ALB), CRP, normalized PCR (nPCR), and Kt/V ratio of urea at baseline (day (D) 0) and at endpoint (M12). The ALB was measured by immunoturbidimetry. Three nutritional profiles were defined, severe UN if ALB ≤ 35 g/L, moderate UN if 35 <ALB <38 g/L, no UN if ALB ≥ 38 g/L. The therapeutic goal is to obtain a target ALB ≥ 38 g/L, protein intake exceeding 1g/kg/d and energy intake exceeding 35 Kcal/kg/d. The criteria of effectiveness are obtaining the ALB defined target, changes in numbers of pts in 3 nutritional profiles and mortality rate on 1 year. We observe a significant improvement in all nutritional indicators at M12. The numbers of pts with severe UN and moderate UN decreased (P < 0,05), respectively from 32 to 14% and from 27 to 18% (D0 versus M12). The UN frequency has been reduced about 50% (P < 0,05) lowering from 59 to 32%. The mortality rate of 4% (5/132 pts) in 1 year was very low. The therapeutic goal is achieved under the conjunction of 3 essential conditions, the improvement of the inflammatory syndrome, an effective dialysis and optimal protein and caloric intake. At the start and the end of the study, the role of inflammation appears crucial because ALB is greater if CRP <10mg/L versus CRP ≥ 10 mg/L (at M12: 40 versus 38 g/L, P = 0.002); an inverse correlation is observed between CRP and ALB (R(2) = 0,080, P = 0.002). An effective NS reduces the frequency of UN in CHD, improves the quality of life the pts and lowers mortality rates. An oral nutritional supplement during dialysis constitutes an important component of treatment. The control of inflammation and optimizing dialysis are decisive factors of success.


  • Hyperparathyroïdie secondaire et anémie. Effets d’un calcimimétique sur le contrôle de l’anémie des hémodialysés chroniques. Étude pilote

    by Ignace Mpio, Nourredine Boumendjel, Husseyin Karaaslan, Walid Arkouche, Alexandra Lenz, Carlos Cardozo, Jorge Cardozo, Myriam Pastural-Thaunat, Denis Fouque, Jacques Silou, et al.

    The main cause of resistance to erythropoiesis-stimulating agents (ESA) used for treatment of anemia in chronic hemodialysed patients (CHP) is the iron deficiency, absolute or functional. Secondary hyperparathyroidism (SHPT) is a secondary factor of resistance. Indeed, it has been reported in the literature an improvement of anemia parameters after surgical parathyroidectomy (PTX). The objective of this study is to assess in CHP, the impact of the correction of SHPT by a calcimimetic, cinacalcet (CI), (which is considered as a pharmacological PTX) on the response to ESA, measured by the erythropoietin resistance index (ERI). Twenty-two CHP with severe SHPT documented by an intact parathyroid hormone (iPTH) above 800pg/mL were included in this prospective pilot study. Mineral bone metabolism, anemia and nutritional parameters were measured baseline and after 6 months of treatment by CI. The effect on anemia was assessed at the end of study by the ERI, the change in Hb concentration, and the proportion of patients with Hb levels above 11g/dL. At the end of study there was a significant decrease (M6 vs M0) in iPTH (1302 vs 674pg/mL or -48%, p=0.006), serum calcium (2.39 vs 2.15mmol/L or -10%), serum phosphate (2 vs 1.7mmol/L or -15%), serum calcium-phosphorus product (CaxP) (4.8 vs 3.8mmol(2)/L(2) or - 20% (p4.4mmol(2)/L(2) (64 vs 32%, p<0.05). The level of bone alkaline phosphatase remained stable during the study (28 vs 27 IU/L). The Hb levels increased from 11 to 11.4g/dL, as did the proportion of patients whose Hb concentration reached 11g/dL or higher (50 vs 70%, p<0.05) without important change of the median weekly ESA dosis in the majority of patients, 18 cases (81%) vs four (19%). Two subgroups were identified from the median decreases in iPTH (delta iPTH) between M0 and M6, Group 1 (delta iPTH≥400pg/mL, n=10) and group 2 (delta iPTH<400pg/mL, n=12): in group 1, we found a correlation between the decrease in iPTH by CI and the stability or decrease in ERI (group 1), at comparable dose of dialysis, nutritional and iron intakes and inflammatory profiles; in group 2 without a significant effect of CI on PTH reduction the levels of ERI and ESA dosis were more elevated. A treatment by calcimimetic improves the control of anemia by ESA in CHP and interferes positively on a cause of secondary resistance to ESA represented by SHPT. The mechanism of these effects could be linked to the decreased of bone marrow fibrosis and inflammation and to the triptych formed by the reduction in iPTH, CaxP and phosphate.